Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

NCT00470470 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

NIH

Sponsor class

Conditions

Acral Lentiginous Malignant Melanoma
Recurrent Melanoma
Stage IIIA Melanoma
Stage IIIB Melanoma
Stage IIIC Melanoma
Stage IV Melanoma

Interventions

DRUG: imatinib mesylate
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)